The scientific evolution of Glucagon-Like Peptide-1 (GLP-1) receptor agonists represents one of the most significant pharmacological developments in modern endocrinology. What began as fundamental research into the physiological incretin effect has evolved over four decades into a highly sophisticated class of synthetic peptides designed to address the biochemical limitations of endogenous hormones.
This review analyzes the scientific history and molecular engineering that facilitated the transition from early clinical observations to the development of advanced analogs, including semaglutide.
Foundational Discoveries: The Incretin Effect
The foundational concept underlying GLP-1 research began in the 1960s with the characterization of the “incretin effect”. In 1964, and later confirmed in 1967 by Perley and Kipnis, researchers documented a key physiological phenomenon: oral glucose administration elicited a substantially more robust insulin response than an equivalent intravenous glucose load. This observation provided the first empirical evidence that gut-derived factors actively regulate insulin secretion.
This led to the isolation of glucose-dependent insulinotropic polypeptide (GIP) in the 1970s, recognized as the first incretin hormone. A major molecular breakthrough occurred in 1983 when Bell and colleagues successfully cloned the preproglucagon gene, demonstrating that glucagon is derived from a larger precursor protein containing glucagon-like peptide sequences.
By 1987, researchers including Mojsov and colleagues successfully identified the biologically active fragment of GLP-1, demonstrating that it functioned as a potent insulinotropic hormone capable of stimulating insulin secretion in a glucose-dependent manner.
The Pharmacokinetic Barrier: DPP-4 Degradation
While early human infusion studies in 1989 proved that exogenous GLP-1 could dramatically impact glucose levels, researchers immediately encountered a significant pharmacokinetic barrier. When the continuous intravenous infusion was halted, the biological effects deteriorated rapidly.
Researchers soon identified the cause: endogenous GLP-1 is subject to rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4). This enzyme cleaves the peptide at the N-terminus, rendering it biologically inactive. Native GLP-1 (7-36 amide) possesses a plasma half-life of merely 1 to 2 minutes when administered intravenously, and roughly 5 minutes following subcutaneous injection. Consequently, unmodified human GLP-1 was therapeutically unviable for sustained use, forcing researchers to explore structural modifications to evade DPP-4 degradation.
The First Generation: Exendin-4 and Exenatide
The critical breakthrough in overcoming the half-life limitation came from an unlikely source. In 1992, Dr. John Eng isolated a peptide called exendin-4 from the venom of the Gila monster (Heloderma suspectum).
Exendin-4 shared approximately 53% amino acid sequence homology with human GLP-1 and, crucially, exhibited powerful binding affinity to the GLP-1 receptor. Because of key structural differences, exendin-4 was naturally resistant to degradation by the human DPP-4 enzyme, providing a significantly longer duration of action.
This discovery provided the molecular scaffold for exenatide, the first synthetic GLP-1 receptor agonist. Exenatide entered the clinical sphere in 2005 as a twice-daily subcutaneous injection. While its pharmacokinetic profile was vastly superior to native GLP-1, researchers immediately began seeking ways to further extend the half-life to improve dosing intervals.
Structural Engineering: The Evolution of Liraglutide
The next major advancement involved moving away from reptilian-derived scaffolds and directly engineering the human GLP-1 sequence. Researchers sought to create a true human GLP-1 analog with an extended half-life.
This led to the development of liraglutide, approved in 2010. The engineering of liraglutide involved a sophisticated structural modification: the attachment of a C16 fatty acid chain (palmitic acid) to the peptide backbone via a glutamic acid spacer.
This lipid conjugation achieved two critical pharmacokinetic alterations:
- It promoted reversible binding to serum albumin in the bloodstream, effectively shielding the peptide from DPP-4 cleavage and renal clearance.
- It facilitated self-association of the peptide molecules into heptamers at the injection site, resulting in delayed systemic absorption.
These modifications extended the half-life of liraglutide to approximately 13 hours, enabling once-daily subcutaneous administration and marking the beginning of the second generation of GLP-1 therapeutics.
Discovery of Incretin Effect (1964-1967)
Researchers prove oral glucose elicits a greater insulin response than intravenous glucose, establishing the role of gut-derived factors.
Identification of GLP-1 (1983-1987)
Preproglucagon gene is cloned, and the active fragment of GLP-1 is shown to stimulate insulin secretion.
Isolation of Exendin-4 (1992)
A DPP-4 resistant peptide mimicking GLP-1 is isolated from Gila monster venom.
Approval of Exenatide (2005)
The first GLP-1 receptor agonist is introduced as a twice-daily injection.
Introduction of Semaglutide (2017)
Advanced molecular modifications yield a highly potent, once-weekly human GLP-1 analog.
The Semaglutide Era: Mastery of Peptide Prolongation
The development of semaglutide, approved for clinical use in 2017, marked a significant advancement in peptide engineering. Semaglutide builds upon the lipidation strategy established with liraglutide, incorporating key refinements to enable a once-weekly dosing regimen.
The structure of semaglutide features three primary modifications to the native human GLP-1 sequence:
- Amino Acid Substitution: An alanine at position 8 is replaced with alpha-aminoisobutyric acid (Aib). This structural change specifically protects the peptide against cleavage by the DPP-4 enzyme.
- Advanced Lipidation: Researchers attached a longer, specifically engineered C18 fatty di-acid chain (stearic acid).
- Optimized Linker: This fatty acid chain is attached via a hydrophilic spacer (PEG-like) to the lysine at position 26.
This precise combination dramatically increased the molecule’s affinity for serum albumin compared to liraglutide, further reducing renal clearance and metabolic degradation. These modifications extended the half-life of semaglutide to approximately 165 hours (roughly one week), enabling steady-state pharmacokinetics with a once-weekly subcutaneous injection.
The Future: Dual-Receptor Agonism
The trajectory of incretin research continues to advance beyond single-receptor targeting. The recent development of tirzepatide represents the current frontier: a dual GIP/GLP-1 receptor agonist. By synthetically engineering a single peptide to activate multiple distinct incretin receptor pathways simultaneously, researchers are currently investigating the synergistic effects of multi-receptor agonism on metabolic regulation.
The progression from the physiological observations of the 1960s to the development of highly modified, long-acting synthetic peptides demonstrates the substantial influence of molecular engineering on clinical pharmacology.
References
Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10. https://doi.org/10.3389/fendo.2019.00155 Cited by: 1224
Mojsov, S., Weir, G. C., & Habener, J. F. (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation, 79(2), 616–619. https://doi.org/10.1172/jci112855 Cited by: 1175
Willard, F. S., Douros, J. D., Gabe, M. B. N., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5. https://doi.org/10.1172/jci.insight.140532 Cited by: 598